| Formulary Chapter 5: Infections - Full Section
|
Notes:
Prescribers must follow the relevant local and national guidance when treating an infection. Some anti-infectives require approval from the local Trust microbiology team for use, consult local guidance for further information.
Not all anti-infectives listed in this chapter will be available in all localities; availability will be guided by local need and resistance patterns.
|
|
| Useful Links |
 Blackpool Teaching Hospitals: Antimicrobial Formulary |
|
British Association for Sexual Health and HIV |
|
Dapsone for the treatment of Dermatitis Herpetiformis, other dermatoses and Vasculitis shared care guideline |
|
East Lancashire Primary Care: Antimicrobial guide primary care |
|
East Lancashire Secondary Care: Antimicrobial guide secondary care |
|
Greater Preston, Chorley and South Ribble/LSCFT/Morecambe Bay Primary Care: NICE Summary of antimicrobial prescribing guidance - managing common infections |
|
Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (App store) |
|
Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (Google) |
|
LSCMMG Recurrent UTI Prophylactic Antibiotic Pathway |
|
NICE CG165: Hepatitis B (chronic): diagnosis and management |
|
NICE CG97: Lower urinary tract symptoms in men: management |
|
NICE NG109: Urinary tract infection (lower): antimicrobial prescribing |
|
NICE NG112: Urinary tract infection (recurrent): antimicrobial prescribing |
|
NICE NG113: Urinary tract infection (catheter-associated): antimicrobial prescribing |
|
NICE NG120: Cough (acute): antimicrobial prescribing |
|
NICE NG125: Surgical site infections: prevention and treatment |
|
NICE NG19: Diabetic foot problems: prevention and management |
|
NICE NG191: COVID-19 rapid guideline: managing COVID-19 |
|
NICE NG240: Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management |
|
NICE NG51: Sepsis: recognition, diagnosis and early management |
|
NICE NG78: Cystic fibrosis: diagnosis and management |
|
University Hospitals of Morecambe Bay: Antimicrobial guide secondary care |
|
West Lancashire Primary Care: Pan Mersey antimicrobial guide |
|
WHO: AWaRe classification of antibiotics for evaluation and monitoring of use, 2023 |
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
|
Table 1. Summary of antibacterial therapy
(0,0)
|
|
|
Table 2. Summary of antibacterial prophylaxis
(0,0)
|
|
05.01.01 |
Penicillins
(0,0)
|
|
05.01.01.01 |
Benzylpenicillin and phenoxymethylpenicillin
(2,0)
|
|
05.01.01.02 |
Penicillinase-resistant penicillins
(3,0)
|
|
05.01.01.03 |
Broad-spectrum penicillins
(4,0)
|
|
05.01.01.04 |
Antipseudomonal penicillins
(1,0)
|
|
05.01.01.05 |
Mecillinams
(1,0)
|
|
05.01.02.01 |
Cephalosporins
(12,0)
|
|
05.01.02.02 |
Carbapenems
(3,0)
|
|
05.01.02.03 |
Other beta-lactums antibiotics
(1,0)
|
|
05.01.03 |
Tetracyclines
(9,0)
|
|
05.01.04 |
Aminoglycosides
(4,0)
|
|
05.01.05 |
Macrolides
(5,0)
|
|
05.01.06 |
Clindamycin
(2,0)
|
|
05.01.07 |
Some other antibacterials
(2,0)
|
|
|
Chloramphenicol
(1,0)
|
|
|
Fosfomycin
(2,0)
|
|
|
Fusidic acid
(1,0)
|
|
|
Glycopeptide antibacterials
(4,0)
|
|
|
Linezolid
(2,0)
|
|
|
Polymyxins
(2,0)
|
|
|
Rifaximin
(2,0)
|
|
|
Fidaxomicin
(1,0)
|
|
05.01.08 |
Sulphonamides and trimethoprim
(3,0)
|
|
05.01.09 |
Antituberculosis drugs
(14,0)
|
|
05.01.10 |
Antileprotic drugs
(2,0)
|
|
05.01.11 |
Metronidazole and tinidazole
(2,0)
|
|
05.01.12 |
Quinolones
(5,0)
|
|
05.02 |
Antifungal drugs
(13,0)
|
|
|
Treatment of fungal infections
(0,0)
|
|
05.02.01 |
Triazole antifungals
(0,0)
|
|
05.02.02 |
Imidazole antifungals
(0,0)
|
|
05.02.03 |
Polyene antifungals
(0,0)
|
|
05.02.04 |
Echinocandin antifungals
(2,0)
|
|
05.03 |
Antiviral drugs
(7,0)
|
|
05.03.01 |
HIV infection
(5,0)
|
|
|
HIV-integrase inhibitors
(4,0)
|
|
|
Nucleoside reverse transcriptase inhibitors
(12,0)
|
|
|
Protease inhibitors
(4,0)
|
|
|
Non-nucleoside reverse transcriptase inhibitors
(4,0)
|
|
|
Other antiretrovirals
(8,0)
|
|
05.03.02.01 |
Herpes simplex and varicella-zoster infection
(4,0)
|
|
05.03.02.02 |
Cytomegalovirus infection
(6,0)
|
|
05.03.03 |
Viral hepatitis
(3,0)
|
|
05.03.03.01 |
Chronic hepatitis B
(0,0)
|
|
05.03.03.02 |
Chronic hepatitis C
(6,0)
|
|
05.03.04 |
Influenza
(3,0)
|
|
05.03.05 |
Respiratory syncytial virus
(2,0)
|
|
05.04 |
Antiprotozoal drugs
(0,0)
|
|
05.04.01 |
Antimalarials
(7,0)
|
|
|
Treatment of malaria
(0,0)
|
|
|
Falciparum malaria (treatment)
(0,0)
|
|
|
Benign malarias (treatment)
(0,0)
|
|
|
Prophylaxis against malaria
(0,0)
|
|
|
Specific recommendations
(0,0)
|
|
|
Artemether with lumefabtrine
(0,0)
|
|
|
Primaquine
(0,0)
|
|
05.04.02 |
Amoebicides
(2,0)
|
|
05.04.03 |
Trichomonacides
(2,0)
|
|
05.04.04 |
Antigiardial drugs
(3,0)
|
|
05.04.06 |
Trypanocides
(0,0)
|
|
05.04.08 |
Drugs for pneumocystis pneumonia
(2,0)
|
|
|
Treatment
(0,0)
|
|
|
Prophylaxis
(0,0)
|
|
05.05 |
Anthelmintics
(2,0)
|
|
05.05.01 |
Drugs for threadworms
(1,0)
|
|
05.05.02 |
Ascaricides
(0,0)
|
|
|
Taenicides
(0,0)
|
|
|
Hydatid disease
(0,0)
|
|
05.05.04 |
Drugs for hookworms
(0,0)
|
|
05.05.06 |
Filaricides
(0,0)
|
|
05.05.08 |
Drugs for strongyloidiasis
(0,0)
|
